Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Listing Update
Date:3/6/2009

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company received a letter from The NASDAQ Stock Market indicating that the NASDAQ Listing Qualifications Panel has determined to continue the listing of the Company's common stock on The NASDAQ Capital Market, subject to the condition that, on or before April 6, 2009, the Company demonstrate compliance with all applicable standards for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or one of its alternatives.

As disclosed on September 6, 2008 and October 10, 2008, the Company was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. At the Company's request, on January 6, 2009, the Panel determined to transfer the listing of the Company's common stock from The NASDAQ Global Market to The NASDAQ Capital Market, subject to the Company demonstrating compliance with the applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009, which period has since been extended through April 6, 2009.

The letter also included a public reprimand in connection with the Company's non-compliance with the shareholder approval and listing of additional shares requirements set forth in Marketplace Rules 4350(i) and 4310(c)(17), respectively, as previously disclosed by the Company in a press release dated January 26, 2009 and Current Report on Form 8-K as filed on January 29, 2009. Those deficiencies have already been remedied.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by April 6, 2009, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
2. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
3. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
4. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
5. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
9. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
10. Pearl Therapeutics Secures $8 Million in Debt Financing
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee to ... of institution presidents and other high-ranking representatives from 35 higher education institutions across ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):